Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients

Are, 2006, Anaplastic thyroid carcinoma biology, pathogenesis, prognostic factors and treatment approaches, Ann Surg Oncol, 13, 453, 10.1245/ASO.2006.05.042

Smallridge, 2009, Anaplastic thyroid cancer molecular pathogenesis and emerging therapies, Endocr Relat Cancer, 16, 17, 10.1677/ERC-08-0154

Aratake, 2006, Coexistent anaplastic and differentiated thyroid carcinoma in immunohistochemical study, Am J Clin Pathol, 125, 399, 10.1309/LF3Q1NQKMT2N9KNV

Hunt, 2003, Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid, Am J Surg Pathol, 27, 1559, 10.1097/00000478-200312000-00009

Wiseman, 2007, Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma, Arch Surg, 142, 717, 10.1001/archsurg.142.8.717

Evans, 2014, A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma, Cancer Biol Ther, 13, 776, 10.4161/cbt.20560

Soares, 2011, Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas, Curr Genomics, 12, 609, 10.2174/138920211798120853

Pita, 2014, Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas, J Clin Endocrinol Metab, 99, 497, 10.1210/jc.2013-1512

Lam, 2000, Insular and anaplastic carcinoma of the thyroid a 45-year comparative study at a single institution and a review of the significance of P53 and P21, Ann Surg, 231, 329, 10.1097/00000658-200003000-00005

Quiros, 2005, Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations, Cancer, 103, 2261, 10.1002/cncr.21073

Fagin, 1993, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, J Clin Invest, 91, 179, 10.1172/JCI116168

Saiz, 2002, Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions, J Pathol, 198, 157, 10.1002/path.1185

Ewen, 2004, The activities of cyclin D1 that drive tumorigenesis, Trends Mol Med, 10, 158, 10.1016/j.molmed.2004.02.005

Wang, 2000, The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer, Mol Pathol, 13, 882, 10.1038/modpathol.3880157

Williams, 1991, Programmed cell death: apoptosis and oncogenesis, Cell, 65, 1097, 10.1016/0092-8674(91)90002-G

Pollina, 1996, bcl2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas, Br J Cancer, 73, 139, 10.1038/bjc.1996.26

Eun, 2011, A polymorphism (rs1801018, Thr7Thr) of BCL2 is associated with papillary thyroid cancer in Korean population, Clin Exp Otorhinolaryngol, 4, 149, 10.3342/ceo.2011.4.3.149

Wiseman, 2011, Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma, Am J Surg, 201, 580, 10.1016/j.amjsurg.2011.01.010

Motti, 2005, Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas, Carcinogenesis, 26, 1021, 10.1093/carcin/bgi050

Salama, 2008, A review of the S100 proteins in cancer, Eur J Surg Oncol, 34, 357, 10.1016/j.ejso.2007.04.009

Ito, 2005, Expression of S100A2 and S100A6 in thyroid carcinomas, Histopathol, 46, 569, 10.1111/j.1365-2559.2005.02137.x

Nishimura, 1997, S-100 protein is a differentiation marker in thyroid carcinoma of follicular cell origin: an immunohistochemical study, Pathol Int, 47, 673, 10.1111/j.1440-1827.1997.tb04440.x

Utrilla, 1999, Expression of c-erbB-2 oncoprotein in human thyroid tumors, Histopatol, 34, 60, 10.1046/j.1365-2559.1999.00563.x

Mdah, 2014, Lack of Her-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer, Mol Clin Oncol, 2, 1107, 10.3892/mco.2014.346

Rebai, 2009, Association of EGFR and HER2 polymorphism with risk and clinical features of thyroid cancer, Genet Test Mol Biomarkers, 13, 779, 10.1089/gtmb.2009.0068

Wieseman, 2003, Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy, Head Neck, 25, 662, 10.1002/hed.10277